Antibody-RNA Conjugates represent a significant advancement in the treatment of challenging and rare diseases with unmet medical need.

Scientists from the National Institutes for Food and Drug Control have characterized antibody-drug conjugates (ADCs) using ...

New CEO James Park Delivers First Presentation at J.P. Morgan Healthcare Conference on 'Advancing as a Global CDMO Leader' ...

Lotte Biologics CEO James Park aims to secure ADC orders at U.S. plant this year Lotte Biologics new leadership seeks to ...

Korea’s top biopharmaceutical firms, Celltrion and Samsung Biologics, envisioned their future strategies for expansion at J.P.Morgan Healthcare Conference (JPM) 2025 in San Francisco, Wednesday.

With over 211 antibody-drug conjugate clinical trials breaking ground so far throughout 2022, a plethora of positive clinical results, expansion of antibody-drug conjugates to novel indications ...

Trophoblast cell surface antigen 2 (TROP2) is a transmembrane glycoprotein that acts as an intracellular calcium signal transducer, frequently overexpressed in cancer and associated with poor ...

(RTTNews) - Biohaven Ltd. (BHVN) and Merus N.V. (MRUS) announced a research collaboration and licensing agreement aimed at co-developing three innovative bispecific antibody drug conjugates (ADCs).

NextCure, Inc. has announced that it has dosed its first patient in a Phase 1 clinical trial for LNCB74, an antibody-drug conjugate targeting B7-H4 for the treatment of multiple cancers.

This industry report offers market estimates and forecasts of the global market, followed by a detailed analysis of the product, process, diseases, and region. The global market for antibody drugs can ...